JP2019511570A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511570A5 JP2019511570A5 JP2018565253A JP2018565253A JP2019511570A5 JP 2019511570 A5 JP2019511570 A5 JP 2019511570A5 JP 2018565253 A JP2018565253 A JP 2018565253A JP 2018565253 A JP2018565253 A JP 2018565253A JP 2019511570 A5 JP2019511570 A5 JP 2019511570A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- aav
- ventricle
- progranulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022030769A JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302525P | 2016-03-02 | 2016-03-02 | |
| US62/302,525 | 2016-03-02 | ||
| PCT/US2017/020397 WO2017151884A1 (en) | 2016-03-02 | 2017-03-02 | Therapy for frontotemporal dementia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022030769A Division JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511570A JP2019511570A (ja) | 2019-04-25 |
| JP2019511570A5 true JP2019511570A5 (enExample) | 2020-03-19 |
| JP7436089B2 JP7436089B2 (ja) | 2024-02-21 |
Family
ID=59743281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565253A Active JP7436089B2 (ja) | 2016-03-02 | 2017-03-02 | 前頭側頭型認知症の治療 |
| JP2022030769A Active JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022030769A Active JP7507808B2 (ja) | 2016-03-02 | 2022-03-01 | 前頭側頭型認知症の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190328906A1 (enExample) |
| EP (1) | EP3423109A4 (enExample) |
| JP (2) | JP7436089B2 (enExample) |
| AU (1) | AU2017227803B2 (enExample) |
| CA (1) | CA3016314A1 (enExample) |
| WO (1) | WO2017151884A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107106689A (zh) | 2014-11-05 | 2017-08-29 | 沃雅戈治疗公司 | 用于治疗帕金森病的aadc多核苷酸 |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| US20190328906A1 (en) * | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
| US20240002459A1 (en) * | 2016-07-14 | 2024-01-04 | Emory University | Granulin Compositions and Uses Related Thereto |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN112553210B (zh) * | 2017-10-03 | 2024-09-24 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| CA3078501A1 (en) | 2017-10-03 | 2019-04-11 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| BR112020006633A2 (pt) | 2017-10-03 | 2020-10-06 | Prevail Therapeutics, Inc. | terapias genéticas para distúrbios lisossômicos |
| CN111819281B (zh) * | 2017-10-23 | 2024-12-31 | 普利维尔治疗公司 | 用于神经变性疾病的基因疗法 |
| JP7401432B2 (ja) * | 2017-12-01 | 2023-12-19 | エンコーデッド セラピューティクス， インコーポレイテッド | 操作されたｄｎａ結合タンパク質 |
| EP3794126A1 (en) | 2018-05-15 | 2021-03-24 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
| CN113383010B (zh) | 2018-09-28 | 2025-09-09 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
| CN113164627B (zh) * | 2018-10-16 | 2024-10-29 | 戴纳立制药公司 | 治疗和监测颗粒体蛋白前体相关病症的方法 |
| EP3917539A4 (en) * | 2019-02-01 | 2022-11-23 | Avrobio, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROCOGNITIVE DISORDERS |
| MX2021010134A (es) * | 2019-02-22 | 2021-09-23 | Univ Pennsylvania | Virus adenoasociado recombinante para el tratamiento de la neurodegeneracion de inicio en adultos asociada a grn. |
| US11999974B2 (en) | 2019-04-10 | 2024-06-04 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| KR20220006527A (ko) | 2019-04-10 | 2022-01-17 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애에 대한 유전자 요법 |
| WO2020243651A1 (en) | 2019-05-29 | 2020-12-03 | Encoded Therapeutics, Inc. | Compositions and methods for selective gene regulation |
| GB201913974D0 (en) | 2019-09-27 | 2019-11-13 | King S College London | Vector |
| MX2022004812A (es) * | 2019-10-22 | 2023-02-23 | Applied Genetic Tech Corporation | Sistemas de virus adeno-asociados (aav) para el tratamiento de enfermedades o trastornos neurodegenerativos asociados a la progranulina. |
| EP4146797A1 (en) * | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| US20230227847A1 (en) * | 2020-05-27 | 2023-07-20 | Universität Zürich | Viral vectors expressing therapeutic proteins specifically in myeloid cells and microglia |
| CN116437968A (zh) * | 2020-08-10 | 2023-07-14 | 普利维尔治疗公司 | 用于神经退行性病症的基因疗法 |
| PH12023550145A1 (en) * | 2020-08-12 | 2024-03-18 | UCB Biopharma SRL | Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences |
| AR123358A1 (es) * | 2020-08-26 | 2022-11-23 | Univ Pennsylvania | Virus adenoasociado recombinante para el tratamiento de la neurodegeneración de inicio adulto asociada a la grn |
| EP4284335A1 (en) | 2021-02-01 | 2023-12-06 | RegenxBio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| WO2024035649A1 (en) * | 2022-08-08 | 2024-02-15 | Shape Therapeutics Inc. | Compositions for progranulin expression and methods of use thereof |
| GB202216168D0 (en) | 2022-10-31 | 2022-12-14 | UCB Biopharma SRL | Route of administration |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101460621B (zh) * | 2006-06-07 | 2016-01-27 | 建新公司 | 肌萎缩性侧索硬化和其他脊髓失调症的基因治疗 |
| EP2249861B1 (en) * | 2008-01-16 | 2016-07-06 | Neurodyn Life Sciences Inc. | Progranulin for use in treating parkinson's disease or alzheimer's disease |
| JP5879256B2 (ja) * | 2009-05-02 | 2016-03-08 | ジェンザイム・コーポレーション | 神経変性障害のための遺伝子治療 |
| US20110203007A1 (en) * | 2010-02-16 | 2011-08-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis |
| US20190328906A1 (en) | 2016-03-02 | 2019-10-31 | The Children's Hospital Of Philadelphia | Therapy for frontotemporal dementia |
-
2017
- 2017-03-02 US US16/081,346 patent/US20190328906A1/en active Pending
- 2017-03-02 CA CA3016314A patent/CA3016314A1/en active Pending
- 2017-03-02 JP JP2018565253A patent/JP7436089B2/ja active Active
- 2017-03-02 EP EP17760789.2A patent/EP3423109A4/en active Pending
- 2017-03-02 WO PCT/US2017/020397 patent/WO2017151884A1/en not_active Ceased
- 2017-03-02 AU AU2017227803A patent/AU2017227803B2/en active Active
-
2022
- 2022-03-01 JP JP2022030769A patent/JP7507808B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528734A5 (enExample) | ||
| JP2020519629A5 (enExample) | ||
| JP2018508519A5 (enExample) | ||
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| JP2016503405A5 (enExample) | ||
| JP2020513811A5 (enExample) | ||
| TW201840850A (zh) | 腺相關病毒載體遞送肌肉特異性微小肌縮蛋白以治療肌肉萎縮症 | |
| JP2021512072A5 (enExample) | ||
| JP2019513779A5 (enExample) | ||
| JP2009526067A5 (enExample) | ||
| JP2017529395A5 (enExample) | ||
| JP2022071067A (ja) | 前頭側頭型認知症の治療 | |
| JP2019537576A5 (enExample) | ||
| JP2021500352A5 (enExample) | ||
| IL262852B1 (en) | Treatment of complement-mediated disorders | |
| CA3025445A1 (en) | Dual overlapping adeno-associated viral vector system for expressing abc4a | |
| JP2020509786A5 (enExample) | ||
| JP2023537358A5 (enExample) | ||
| JP2021520811A5 (enExample) | ||
| JP2023065516A5 (enExample) | ||
| JP2023515795A5 (enExample) | ||
| JP2021511020A5 (enExample) | ||
| IL319564A (en) | BAG 3 methods and uses for treating cardiac amyloidosis | |
| JP2020510433A5 (enExample) | ||
| JP2022545378A5 (enExample) |